Cyclo Therapeutics, Inc. (CYTH)
NASDAQ: CYTH · IEX Real-Time Price · USD
1.260
-0.070 (-5.26%)
At close: Apr 26, 2024, 4:00 PM
1.300
+0.040 (3.17%)
After-hours: Apr 26, 2024, 4:00 PM EDT

Cyclo Therapeutics Revenue

In the year 2023, Cyclo Therapeutics had annual revenue of $1.08M, a decrease of -21.76%. Revenue in the quarter ending December 31, 2023 was $311.40K with 66.70% year-over-year growth.

Revenue (ttm)
$1.08M
Revenue Growth
-21.76%
P/S Ratio
33.61
Revenue / Employee
$134,551
Employees
8
Market Cap
36.18M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20231.08M-299.36K-21.76%
Dec 31, 20221.38M-210.00K-13.24%
Dec 31, 20211.59M682.38K75.54%
Dec 31, 2020903.38K-103.82K-10.31%
Dec 31, 20191.01M-4.28K-0.42%
Dec 31, 20181.01M-226.28K-18.28%
Dec 31, 20171.24M-265.15K-17.64%
Dec 31, 20161.50M552.45K58.13%
Dec 31, 2015950.46K-616.98K-39.36%
Dec 31, 20141.57M-125.90K-7.43%
Dec 31, 20131.69M648.39K62.05%
Dec 31, 20121.04M13.09K1.27%
Dec 31, 20111.03M229.48K28.60%
Dec 31, 2010802.37K178.50K28.61%
Dec 31, 2009623.87K128.94K26.05%
Dec 31, 2008494.94K-256.24K-34.11%
Dec 31, 2007751.18K208.86K38.51%
Dec 31, 2006542.31K87.95K19.36%
Dec 31, 2005454.36K-10.33K-2.22%
Dec 31, 2004464.69K70.16K17.78%
Dec 31, 2003394.53K-127.84K-24.47%
Dec 31, 2002522.37K232.95K80.49%
Dec 31, 2001289.43K30.47K11.77%
Dec 31, 2000258.96K-233.17K-47.38%
Dec 31, 1999492.13K271.31K122.87%
Dec 31, 1998220.82K-78.30K-26.18%
Dec 31, 1997299.12K-44.95K-13.06%
Dec 31, 1996344.07K--
Dec 31, 1995---
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Owlet 54.01M
LENSAR 42.16M
ImmunoPrecise Antibodies 17.67M
Co-Diagnostics 6.81M
VYNE Therapeutics 424.00K
Revenue Rankings